Company Overview of Visterra, Inc.
Visterra, Inc., a clinical-stage biopharmaceutical company, focuses on applying its Hierotope platform to identify unique disease targets and to design and engineer antibody-based therapies that are intended to be effective as a single-dose administration. Its lead product candidate is VIS410, a monoclonal antibody (mAb) that is in Phase IIa clinical trials for the treatment of hospitalized patients with influenza A. The company also develops VIS513, a mAb for the treatment of dengue. Its early-stage programs include antibody-based programs VIS-FLX for the prevention of influenza A in high-risk populations. Visterra, Inc. has collaboration and license agreements with Massachusetts Institute ...
One Kendall Square
Cambridge, MA 02139
Founded in 2007
Key Executives for Visterra, Inc.
Chief Executive Officer, President and Director
Founder and Chairman of the Board
Chief Financial Officer and Chief Operating Officer
Senior Vice President of Business Development & Strategic Planning
Compensation as of Fiscal Year 2017.
Visterra, Inc. Key Developments
Visterra, Inc. Announces Publication in the Journal PLOS Neglected Tropical Diseases Demonstrating Novel Antibody, VIS513, Broadly Neutralizes Antibody-Enhanced Dengue Infection in Preclinical Studies
Feb 12 18
Visterra, Inc. announced that new preclinical results with VIS513, its novel monoclonal antibody in development for the treatment of dengue, were published online in the journal PLOS Neglected Tropical Diseases (Y. Budigi et al., PLoS Negl Trop Dis 12(2): e0006209. In the paper titled “Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein,” Visterra scientists and scientists at the National University of Singapore (NUS), the Singapore-MIT Alliance for Research and Technology (SMART) Center, and Duke-National University of Singapore (Duke-NUS) describe preclinical data demonstrating that VIS513 potently neutralized dengue virus at clinically relevant viral loads. More importantly, dengue virus neutralization by VIS513 was demonstrated in the presence of natural antibody that can potentially enhance dengue infection and lead to more severe disease. These data support the continued development of VIS513 as a single administration treatment for dengue virus infection.
Visterra, Inc. Presents at BIO One-on-One Partnering™, Jan-07-2018
Dec 14 17
Visterra, Inc. Presents at BIO One-on-One Partnering™, Jan-07-2018 . Venue: San Francisco, California, United States.
Visterra, Inc. Presents at 2nd Annual Superbugs & Superdrugs USA Conference, Nov-13-2017 04:40 PM
Nov 9 17
Visterra, Inc. Presents at 2nd Annual Superbugs & Superdrugs USA Conference, Nov-13-2017 04:40 PM. Venue: Iselin, New Jersey, United States. Speakers: Obadiah Plante, Director of Research.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|